Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fufang Zanghuixiang enteric soft capsule (also known as Compound Caraway Enteric Liquid Capsule) is a fixed-dose combination herbal medicine containing caraway oil and peppermint oil. Jointly developed by the Tianjin Institute of Pharmaceutical Research and Hebei Aierhaitai Pharmaceutical, it is formulated as an enteric-coated soft capsule designed to release its active ingredients directly in the duodenum, minimizing gastric irritation. The primary active components, menthol (from peppermint oil) and carvone/limonene (from caraway oil), exert synergistic spasmolytic, analgesic, and carminative effects. Menthol acts as a local calcium channel blocker to relax gastrointestinal smooth muscle and activates TRPM8/TRPA1 channels, while carvone acts as an antagonist of the aryl hydrocarbon receptor (AhR) and reduces nerve excitability. The drug is currently in Phase 3 clinical development in China for the treatment of functional dyspepsia, including epigastric pain syndrome (EPS) and postprandial distress syndrome (PDS).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fufang Zanghuixiang enteric soft capsule.